Sprintome
@sprintome.bsky.social
AI + Drug Discovery | Your front-row seat to the future of medicine
https://sprintome.substack.com
https://sprintome.substack.com
🎯 Early traction: Five days ago Blueprint Medicines doubled down on its VantAI alliance, explicitly citing Neo-1, refining aim towards targets previously considered undruggable through conventional methods.
Neo-1 has also been cited in partnerships with giants like BMS and J&J
Neo-1 has also been cited in partnerships with giants like BMS and J&J
May 25, 2025 at 5:15 PM
🎯 Early traction: Five days ago Blueprint Medicines doubled down on its VantAI alliance, explicitly citing Neo-1, refining aim towards targets previously considered undruggable through conventional methods.
Neo-1 has also been cited in partnerships with giants like BMS and J&J
Neo-1 has also been cited in partnerships with giants like BMS and J&J
Why care? Lead-opt chemists spend weeks rigidifying glues to boost cooperativity.
Neo-1 cranks out stiffer scaffolds in a single pass – which could compress that cycle to hours.
Neo-1 cranks out stiffer scaffolds in a single pass – which could compress that cycle to hours.
May 25, 2025 at 5:15 PM
Why care? Lead-opt chemists spend weeks rigidifying glues to boost cooperativity.
Neo-1 cranks out stiffer scaffolds in a single pass – which could compress that cycle to hours.
Neo-1 cranks out stiffer scaffolds in a single pass – which could compress that cycle to hours.
Inference-time steerable generation, not just sampling.
Neo-1 drafts an entire sketch of the molecule, then iteratively refines it, so every atom can be nudged by later context. No more getting stuck with a bad first bond like in autoregressive chains.
Neo-1 drafts an entire sketch of the molecule, then iteratively refines it, so every atom can be nudged by later context. No more getting stuck with a bad first bond like in autoregressive chains.
May 25, 2025 at 5:15 PM
Inference-time steerable generation, not just sampling.
Neo-1 drafts an entire sketch of the molecule, then iteratively refines it, so every atom can be nudged by later context. No more getting stuck with a bad first bond like in autoregressive chains.
Neo-1 drafts an entire sketch of the molecule, then iteratively refines it, so every atom can be nudged by later context. No more getting stuck with a bad first bond like in autoregressive chains.
Until recently, drug designers ran 2 separate models:
1. A model like AlphaFold/ESMFold to predict a target’s 3D fold
2. Another generative or diffusion model to craft binders.
Neo-1 collapses those steps, predicting the complex and generating new ligands in a single pass.
1. A model like AlphaFold/ESMFold to predict a target’s 3D fold
2. Another generative or diffusion model to craft binders.
Neo-1 collapses those steps, predicting the complex and generating new ligands in a single pass.
May 25, 2025 at 5:14 PM
Until recently, drug designers ran 2 separate models:
1. A model like AlphaFold/ESMFold to predict a target’s 3D fold
2. Another generative or diffusion model to craft binders.
Neo-1 collapses those steps, predicting the complex and generating new ligands in a single pass.
1. A model like AlphaFold/ESMFold to predict a target’s 3D fold
2. Another generative or diffusion model to craft binders.
Neo-1 collapses those steps, predicting the complex and generating new ligands in a single pass.
Neo-1, billed as “the world’s most advanced atomistic foundation model,” unifies structure prediction and all-atom de-novo generation in a single neural core.
May 25, 2025 at 5:14 PM
Neo-1, billed as “the world’s most advanced atomistic foundation model,” unifies structure prediction and all-atom de-novo generation in a single neural core.
VantAI and Blueprint Medicines are revising their partnership to tackle "historically undruggable targets," citing the use of Neo-1, VantAI's foundation model, as key to the partnership.
The deal includes up to $1.67 Billion in future milestone payments.
So what is Neo-1? 🧵
The deal includes up to $1.67 Billion in future milestone payments.
So what is Neo-1? 🧵
May 25, 2025 at 5:13 PM
VantAI and Blueprint Medicines are revising their partnership to tackle "historically undruggable targets," citing the use of Neo-1, VantAI's foundation model, as key to the partnership.
The deal includes up to $1.67 Billion in future milestone payments.
So what is Neo-1? 🧵
The deal includes up to $1.67 Billion in future milestone payments.
So what is Neo-1? 🧵
Streamlined approvals, accepting foreign trial data, a strong education/research ecosystem, and highly competitive manufacturing capabilities are powering this wave of Chinese biotech successes.
The DeepSeek moment of biotech? 🌊
It's been in the works for some time.
The DeepSeek moment of biotech? 🌊
It's been in the works for some time.
May 17, 2025 at 12:59 PM
Streamlined approvals, accepting foreign trial data, a strong education/research ecosystem, and highly competitive manufacturing capabilities are powering this wave of Chinese biotech successes.
The DeepSeek moment of biotech? 🌊
It's been in the works for some time.
The DeepSeek moment of biotech? 🌊
It's been in the works for some time.
1. The 'implied license" policy, automatically authorizing any clinical trials if no objections are voiced within 60 days ⚡️
2. China updated its rules to accept overseas clinical trial data, reducing the need to repeat entire studies within China 🌏
2. China updated its rules to accept overseas clinical trial data, reducing the need to repeat entire studies within China 🌏
May 17, 2025 at 12:59 PM
1. The 'implied license" policy, automatically authorizing any clinical trials if no objections are voiced within 60 days ⚡️
2. China updated its rules to accept overseas clinical trial data, reducing the need to repeat entire studies within China 🌏
2. China updated its rules to accept overseas clinical trial data, reducing the need to repeat entire studies within China 🌏
The Biotech 'DeepSeek' moment?
China’s DeepSeek moment in biotech is already here, says Simone Song, founder at Hong Kong-based VC firm ORI Capital. 🧶
China’s DeepSeek moment in biotech is already here, says Simone Song, founder at Hong Kong-based VC firm ORI Capital. 🧶
May 17, 2025 at 12:59 PM
The Biotech 'DeepSeek' moment?
China’s DeepSeek moment in biotech is already here, says Simone Song, founder at Hong Kong-based VC firm ORI Capital. 🧶
China’s DeepSeek moment in biotech is already here, says Simone Song, founder at Hong Kong-based VC firm ORI Capital. 🧶
Don't get left behind 👇
sprintome.substack.com
sprintome.substack.com
May 12, 2025 at 10:27 AM
Don't get left behind 👇
sprintome.substack.com
sprintome.substack.com
H-optimus-1 now on AWS Marketplace means faster, secure deployment of cutting-edge pathology AI for *all* organizations, commercial and academic 🌍.
May 12, 2025 at 10:27 AM
H-optimus-1 now on AWS Marketplace means faster, secure deployment of cutting-edge pathology AI for *all* organizations, commercial and academic 🌍.
Model features include integrated EHR data ingestion, patient stratification simulations, and safety‑signal predictions—backed by partnerships with top pharma firms.
Don't miss out on the latest!
#Sprintome #JoinTheSprint
sprintome.substack.com
Don't miss out on the latest!
#Sprintome #JoinTheSprint
sprintome.substack.com
May 9, 2025 at 9:03 PM
Model features include integrated EHR data ingestion, patient stratification simulations, and safety‑signal predictions—backed by partnerships with top pharma firms.
Don't miss out on the latest!
#Sprintome #JoinTheSprint
sprintome.substack.com
Don't miss out on the latest!
#Sprintome #JoinTheSprint
sprintome.substack.com
💡 QuantHealth just unveiled the first Pharmaco‑Clinical Foundation Model, built to power clinical trial simulation and real‑world evidence generation for drug development.
Progression-free survival in a multiple myeloma trial for 1L patients 👇
quanthealth.ai
Progression-free survival in a multiple myeloma trial for 1L patients 👇
quanthealth.ai
May 9, 2025 at 9:03 PM
💡 QuantHealth just unveiled the first Pharmaco‑Clinical Foundation Model, built to power clinical trial simulation and real‑world evidence generation for drug development.
Progression-free survival in a multiple myeloma trial for 1L patients 👇
quanthealth.ai
Progression-free survival in a multiple myeloma trial for 1L patients 👇
quanthealth.ai
FDA chief Martin Makary has ordered every agency center to bake generative-AI tools into routine workflows by end of June, after a successful pilot for scientific reviewers. The goal: strip out busywork and speed approvals of new therapies.
May 9, 2025 at 12:15 PM
FDA chief Martin Makary has ordered every agency center to bake generative-AI tools into routine workflows by end of June, after a successful pilot for scientific reviewers. The goal: strip out busywork and speed approvals of new therapies.
Academic oncologist Vinay Prasad, known for his sharp critiques of Covid policies and the FDA’s ties to pharma, has been tapped to head the FDA Center for Biologics Evaluation and Research.
He is succeeding Peter Marks after he was ousted in March by Health Secretary RFK Jr.
He is succeeding Peter Marks after he was ousted in March by Health Secretary RFK Jr.
May 9, 2025 at 12:05 PM
Academic oncologist Vinay Prasad, known for his sharp critiques of Covid policies and the FDA’s ties to pharma, has been tapped to head the FDA Center for Biologics Evaluation and Research.
He is succeeding Peter Marks after he was ousted in March by Health Secretary RFK Jr.
He is succeeding Peter Marks after he was ousted in March by Health Secretary RFK Jr.
“Past outcomes have made one thing clear: trying to sell pharma companies research in the form of discovery software is an attempt to ‘vendorize’ an extremely complicated and inherently proprietary process.”
May 7, 2025 at 1:48 AM
“Past outcomes have made one thing clear: trying to sell pharma companies research in the form of discovery software is an attempt to ‘vendorize’ an extremely complicated and inherently proprietary process.”
May 5, 2025 at 11:19 AM
Recursion is trimming its pipeline from 11 to 7 programs, prioritizing cancer and rare diseases.
May 5, 2025 at 11:19 AM
Recursion is trimming its pipeline from 11 to 7 programs, prioritizing cancer and rare diseases.
This sets a new standard for understanding cellular diversity across evolutionary gaps 🧠
Paper: www.biorxiv.org/content/10.1...
You know what to do 👇
sprintome.substack.com
#JoinTheSprint
Paper: www.biorxiv.org/content/10.1...
You know what to do 👇
sprintome.substack.com
#JoinTheSprint
May 1, 2025 at 3:49 AM
This sets a new standard for understanding cellular diversity across evolutionary gaps 🧠
Paper: www.biorxiv.org/content/10.1...
You know what to do 👇
sprintome.substack.com
#JoinTheSprint
Paper: www.biorxiv.org/content/10.1...
You know what to do 👇
sprintome.substack.com
#JoinTheSprint
TranscriptFormer trains on over 112 million cells across 12 species, spanning 1.53 billion years of evolution.
May 1, 2025 at 3:49 AM
TranscriptFormer trains on over 112 million cells across 12 species, spanning 1.53 billion years of evolution.
April 30, 2025 at 5:14 AM
AlphaFold takes too long because of MSAs.
Models like OmegaFold, ESMFold, Chai-1 tackle this bottleneck by removing the need for MSAs and learning evolutionary relationships implicitly.
So what is MiniFold? 🧵
Models like OmegaFold, ESMFold, Chai-1 tackle this bottleneck by removing the need for MSAs and learning evolutionary relationships implicitly.
So what is MiniFold? 🧵
April 30, 2025 at 5:14 AM
AlphaFold takes too long because of MSAs.
Models like OmegaFold, ESMFold, Chai-1 tackle this bottleneck by removing the need for MSAs and learning evolutionary relationships implicitly.
So what is MiniFold? 🧵
Models like OmegaFold, ESMFold, Chai-1 tackle this bottleneck by removing the need for MSAs and learning evolutionary relationships implicitly.
So what is MiniFold? 🧵
🤖With a 98.5% success rate in early clinical trials, Hugo is charting a promising course for robotic-assisted urology.
April 30, 2025 at 5:02 AM
🤖With a 98.5% success rate in early clinical trials, Hugo is charting a promising course for robotic-assisted urology.
A shift is happening: from slow diffusion methods to flow-matching models like FLOWR.
These models deliver higher structural fidelity and cut inference times dramatically.
Paper: arxiv.org/html/2504.10...
These models deliver higher structural fidelity and cut inference times dramatically.
Paper: arxiv.org/html/2504.10...
April 29, 2025 at 4:06 AM
A shift is happening: from slow diffusion methods to flow-matching models like FLOWR.
These models deliver higher structural fidelity and cut inference times dramatically.
Paper: arxiv.org/html/2504.10...
These models deliver higher structural fidelity and cut inference times dramatically.
Paper: arxiv.org/html/2504.10...
Traditional protein annotation depends heavily on similarity to known proteins—limiting discovery in the uncharted universe of uncharacterized genes.
April 29, 2025 at 12:55 AM
Traditional protein annotation depends heavily on similarity to known proteins—limiting discovery in the uncharted universe of uncharacterized genes.